DENVER – Topical roflumilast (Zoryve) cream 0.05% showed favorable efficacy and safety in children 3 months to up to 2 years of age with mild-to-moderate atopic dermatitis, according to new data presented at the annual American Academy of Dermatology 2026 Annual Meeting.
For example, 34.4% of 96 infants treated daily for 4 weeks successfully achieved a score of 0 (clear) or 1 (almost clear) with a...
The strongest version of this narrative is that roflumilast cream 0.05% offers a safe and effective nonsteroidal treatment option for infants with atopic dermatitis, addressing a critical gap in pediatric dermatology. The data presented—including rapid itch relief and significant improvements in disease severity—are compelling, especially given the limited alternatives for this age group. The study’s focus on scalp dermatitis, a particularly challenging area, adds depth to the findings, and the ...